Vera Health and OpenEvidence, two of the more prominent clinical answer engines currently competing for clinician attention, have each developed meaningfully since earlier comparisons of this kind were written. This update reflects Vera's ACEP partnership and expanded calculator library alongside OpenEvidence's EvidenceGrade feature, and positions iatroX as the UK-oriented third option relevant to readers of this comparison specifically.
Comparing current access models
Vera Health positions itself around genuinely international, free access for verified clinicians and trainees, without a restrictive national verification requirement standing between a clinician outside the US and the core product. OpenEvidence has built a particularly strong US clinician orientation, historically requiring a US National Provider Identifier for verification, and has, at various points, faced geographic access restrictions outside the US that are worth checking directly against current status given how frequently this specific detail changes.
Comparing the platforms directly
Evidence grading exists on both platforms in different forms: Vera's company-described grading logic applied before generating an answer, against OpenEvidence's EvidenceGrade, a real-time, GRADE-inspired letter-grading system applied to individual gradeable claims, covered in detail elsewhere in this content series. Citation transparency is a genuine strength of both platforms, each surfacing inline citations linking specific claims back to underlying sources, though the specific granularity and presentation differ. Premium publisher relationships differ in kind: OpenEvidence's partnership with Cochrane surfaces gold-standard systematic reviews directly within its workflow, while Vera's ACEP partnership brings a specific professional society's clinical policies directly into its answers, a different but comparably significant kind of authoritative content relationship. Calculators favour Vera Health substantially, given its library of more than 900 integrated tools. CME exists on Vera Health as a bundled, automatic feature; OpenEvidence's own professional-development functionality should be checked directly against its current offering. Mobile tools are a genuine strength for both platforms, each having invested in dedicated, actively maintained apps. Professional-society partnerships now exist for both, Vera with ACEP and OpenEvidence with AAO-HNSF, reflecting a broader industry pattern of direct content relationships covered in more depth elsewhere in this series. And funding models differ in ways worth understanding directly rather than assumed: both are venture-backed, and neither has published a fully transparent account of long-term monetisation strategy beyond what has been publicly announced.
What both platforms now compete on
It is worth stating plainly that both platforms have moved beyond competing purely on citation quantity. They increasingly compete on evidence quality specifically, through their respective grading approaches; on workflow breadth, extending beyond pure question-answering into calculators, team functionality and professional development; and on trust and institutional legitimacy, evidenced by their respective direct partnerships with recognised professional bodies.
Recent developments worth noting directly
Vera Health's ACEP partnership and its now-extensive calculator library, both covered in detail elsewhere in this content series, represent genuine recent expansion. OpenEvidence's EvidenceGrade feature and its continuing enterprise expansion, including institutional deployments, represent a parallel pattern of growth into adjacent capability and market segments. Both companies are, in different ways, moving from a narrower original product identity towards a broader clinical AI platform.
Introducing iatroX as the UK-oriented third option
For UK clinicians specifically, neither Vera Health nor OpenEvidence, however strong each is within its own primary market orientation, offers the same depth of NICE, CKS and medicines-specific relevance that a UK-founded platform provides by design. iatroX combines this UK regulatory and guideline positioning, including UKCA marking and MHRA registration for its clinical decision-support functionality specifically, with an integrated learning and examination ecosystem neither Vera Health nor OpenEvidence currently offers in comparable UK-specific form.
Avoiding unsupported superiority claims
Neither Vera Health nor OpenEvidence has published benchmark scores or user figures independently audited by a neutral third party, and any comparison, including this one, should label such figures clearly as vendor reported rather than presenting them as independently established fact. This applies with equal force to any claims iatroX itself might make; readers evaluating any of these three platforms are well served applying the same standard of scrutiny consistently, regardless of which company is making the claim.
A closing note on how to actually choose
Rather than searching for a single universal winner between these two well-resourced, genuinely capable platforms, the more useful exercise for any individual clinician is running the same specific, realistic clinical questions through each one directly, checking citation quality, evidence grading behaviour, and geographic and jurisdictional relevance against their own actual practice, before committing to either as a primary tool.